Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial

Authors: Radner, Martin ^a, Burmeister, Sandy ^b, Jóźwiak, Katarzyna ^b, Schaumann, Nora ^a, Gronewold, Malte ^a, Raap, Mieke ^a, Bartels, Stephan ^a, Christgen, Henriette ^a, Kandt, Leonie D. ^a, Hillmann, Pia ^a, Lehmann, Ulrich ^a, Gluz, Oleg ^{c, d}, Graeser, Monika ^{c, d}, Kümmel, Sherko ^{c, e, f}, Eulenburg, Christine zu ^c, Harbeck, Nadia ^{c, g}, Kreipe, Hans ^a, Christgen, Matthias ^{a, ∗}

Source: In Laboratory Investigation June 2025 105(6)

Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium

Authors: De Schepper, Maxim, Koorman, Thijs, Richard, François, Christgen, Matthias, Vincent-Salomon, Anne, Schnitt, Stuart J., van Diest, Paul J., Zels, Gitte, Mertens, Freya, Maetens, Marion, Vanden Bempt, Isabelle, Harbeck, Nadia, Nitz, Ulrike, Gräser, Monika, Kümmel, Sherko, Gluz, Oleg, Weynand, Birgit, Floris, Giuseppe, Derksen, Patrick W.B., Desmedt, Christine

Source: In Modern Pathology July 2024 37(7)

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance

Authors: Mueller, Sophie, Grote, Isabel, Bartels, Stephan, Kandt, Leonie, Christgen, Henriette, Lehmann, Ulrich, Gluz, Oleg, Graeser, Monika, Kates, Ron, Harbeck, Nadia, Kreipe, Hans, Christgen, Matthias

Source: In Modern Pathology April 2023 36(4)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer

Authors: Grote, Isabel, Bartels, Stephan, Christgen, Henriette, Radner, Martin, Gronewold, Malte, Kandt, Leonie, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Graeser, Monika, Kuemmel, Sherko, Nitz, Ulrike, Harbeck, Nadia, Kreipe, Hans, Christgen, Matthias

Source: In Modern Pathology December 2022 35(12):1804-1811

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.

Authors: Kuemmel, Sherko^1,2,3 (AUTHOR) s.kuemmel@kem-med.com, Graeser, Monika^1,4,5 (AUTHOR), Schmid, Peter⁶ (AUTHOR), Reinisch, Mattea^2,3 (AUTHOR), Feuerhake, Friedrich^7,8 (AUTHOR), Volk, Valery⁷ (AUTHOR), Armeanu-Ebinger, Sorin⁹ (AUTHOR), Schütz, Leon⁹ (AUTHOR), Kelemen, Olga⁹ (AUTHOR), Schroeder, Christopher⁹ (AUTHOR), Ossowski, Stephan⁹ (AUTHOR), Jóźwiak, Katarzyna¹⁰ (AUTHOR), Kostara, Athina¹¹ (AUTHOR), Scheffen, Iris^1,4 (AUTHOR), Lüdtke-Heckenkamp, Kerstin¹² (AUTHOR), Hilpert, Felix¹³ (AUTHOR), Kentsch, Angela¹⁴ (AUTHOR), Ziske, Carsten¹⁵ (AUTHOR), Depenbusch, Reinhard¹⁶ (AUTHOR), Braun, Michael¹⁷ (AUTHOR)

Source: Lancet Oncology. May2025, Vol. 26 Issue 5, p629-640. 12p.

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Authors: von Schumann, Raquel, Kuhn, Walther, Polata, Silke, Bielecki, Wojciech, Meyer, Ralf, Just, Marianne, Kraudelt, Susanne, Siggelkow, Wulf, Wortelmann, Heidi, Kleine-Tebbe, Anke, Leitzen, Lena, Kirchhof, Heidrun, Krabisch, Petra, Hackmann, John, Depenbusch, Reinhard, Gnauert, Karsten, Staib, Peter, Lehnert, Antje, Hoffmann, Oliver, Briest, Susanne, Lindner, Christoph, Heyl, Volker, Bauer, Leila, Uleer, Christoph, Mohrmann, Svjetlana, Viehstaedt, Nicole, Malter, Wolfram, Link, Theresa, Buendgen, Nana, Tio, Joke, Nitz, Ulrike ^*, Gluz, Oleg ^*, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia ^*

Source: In The Lancet Oncology May 2022 23(5):625-635

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

Authors: Graeser, Monika, Harbeck, Nadia, Gluz, Oleg, Würstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Dimpfl, Moritz, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kümmel, Sherko, Nitz, Ulrike

Source: In The Breast October 2021 59:58-66

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.

Authors: Schmidt, Gilda, Gluz, Oleg, Christgen, Matthias, Reinisch, Mattea, Kümmel, Sherko, Nitz, Ulrike, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Mahlberg, Rolf, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Stefek, Andrea, Wuerstlein, Rachel, Graeser, Monika, Jóźwiak, Katarzyna

Source: Breast Cancer Research; 2/14/2025, Vol. 27 Issue 1, p1-15, 15p

Subject Terms: PROPORTIONAL hazards models, IN situ hybridization, PROGRESSION-free survival, MEDICAL sciences, GENE expression

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

Authors: Cornelia Kolberg-Liedtke, Gluz Oleg, Heinisch Fred, Feuerhake Friedrich, Kreipe Hans, Clemens Michael, Nuding Benno, Malter Wolfram, Reimer Toralf, Wuerstlein Rachel, Graeser Monika, Shak Steve, Nitz Ulrike, Kates Ronald, Christgen Matthias, Harbeck Nadia

Source: Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2020)

Subject Terms: Tumor-infiltrating lymphocytes (TILs), Adjuvant chemotherapy, Breast cancer, Disease-free survival, Hormone receptor status, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s13058-020-01283-w; https://doaj.org/toc/1465-542X

Access URL: https://doaj.org/article/8ea47de415e540d2b018174d9ff366c8

HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation.

Authors: Graeser, Monika, Gluz, Oleg

Source: Breast Care; 2023, Vol. 18 Issue 6, p455-463, 9p

Subject Terms: BREAST cancer prognosis, EPIDERMAL growth factor receptors, TRASTUZUMAB, MONOCLONAL antibodies, ANTINEOPLASTIC agents, TREATMENT duration, INDIVIDUALIZED medicine, TUMOR classification, COMBINED modality therapy, TUMOR markers, BREAST tumors

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.

Authors: Gluz, Oleg, Nitz, Ulrike A., Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Schumacher, Johannes, Hartkopf, Andreas, Potenberg, Jochem, Lüedtke-Heckenkamp, Kerstin, Just, Marianne, Schem, Christian, von Schumann, Raquel, Kolberg-Liedtke, Cornelia, Eulenburg, Christine Zu, Schinköthe, Timo, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E., Kreipe, Hans Heinrich, Harbeck, Nadia

Source: JAMA Oncology; Jul2023, Vol. 9 Issue 7, p946-954, 9p

Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions.

Authors: Gluz, Oleg, Graeser, Monika

Source: Current Oncology Reports; May2023, Vol. 25 Issue 5, p491-500, 10p

Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors: Richters, Lisa, Gluz, Oleg, Weber-Lassalle, Nana, Christgen, Matthias, Haverkamp, Heinz, Kuemmel, Sherko, Kayali, Mohamad, Kates, Ronald E., Grischke, Eva-Maria, Altmüller, Janine, Forstbauer, Helmut, Thiele, Holger, Braun, Michael, Warm, Mathias, Ossowski, Anna, Wuerstlein, Rachel, Ernst, Corinna, Graeser, Monika, Linn, Sabine C., Nitz, Ulrike

Source: JAMA Network Open; 2/26/2025, Vol. 8 Issue 2, pe2461639-e2461639, 1p

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.

Authors: Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, Harbeck, Nadia

Source: Breast Cancer Research; 9/2/2022, Vol. 24 Issue 1, p1-13, 13p

Subject Terms: TRIPLE-negative breast cancer, NEOADJUVANT chemotherapy, TUMOR-infiltrating immune cells, PATIENT selection, CLINICAL trials, RECTAL cancer

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.

Authors: Grote, Isabel, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko, zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva‐Maria, Schumacher, Claudia, Luedtke‐Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika

Source: Cancer Medicine; Dec2021, Vol. 10 Issue 23, p8581-8594, 14p

Subject Terms: BREAST cancer, CANCER relapse, HORMONE receptor positive breast cancer, GENETIC mutation, FLUORESCENCE in situ hybridization, HORMONE therapy, METASTATIC breast cancer, NUCLEOTIDE sequencing, ENTEROENDOCRINE cells

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.

Authors: Graeser, Monika, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Würstlein, Rachel, Kümmel, Sherko, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Christgen, Matthias, Adams, Jascha, Nitzsche, Henrik, Just, Marianne, Fischer, Hans Holger, Aktas, Bahriye, Potenberg, Jochem, Schumann, Raquel von, Kolberg-Liedtke, Cornelia, Harbeck, Nadia

Source: International Journal of Cancer; May2021, Vol. 148 Issue 10, p2614-2627, 14p

Subject Terms: MAGNETIC resonance imaging, ULTRASONIC imaging, CANCER relapse, BREAST cancer, RECEIVER operating characteristic curves, RECTAL cancer, KI-67 antigen

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.

Authors: Graeser, Monika, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Herzog, Christopher, Umutlu, Lale, Frydrychowicz, Alex, Rjosk-Dendorfer, Dorothea, Würstlein, Rachel, Culemann, Ralph, Eulenburg, Christine, Adams, Jascha, Nitzsche, Henrik, Prange, Anna, Kümmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Potenberg, Jochem, von Schumann, Raquel

Source: Breast Cancer Research; 3/18/2021, Vol. 23 Issue 1, p1-13, 13p

Subject Terms: MAGNETIC resonance imaging, HORMONE receptor positive breast cancer, ULTRASONIC imaging, EPIDERMAL growth factor receptors, BREAST cancer

Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.

Authors: Wuerstlein, Rachel, Harbeck, Nadia, Grischke, Eva-Maria, Forstmeyer, Dirk, von Schumann, Raquel, Krabisch, Petra, Lüdtke-Heckenkamp, Kerstin, Stefek, Andrea, Stoetzer, Oliver, Grafe, Andrea, Kaltenecker, Gabriele, Forstbauer, Helmut, Augustin, Doris, Schrader, Iris, Tio, Joke, Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E., Graeser, Monika Karla

Source: Breast Care; 2021, Vol. 16 Issue 1, p50-58, 9p

Subject Terms: BREAST tumors, CANCER patients, COMBINED modality therapy, FEBRILE neutropenia, GRANULOCYTE-colony stimulating factor, PREVENTIVE medicine, NEUTROPENIA, TREATMENT effectiveness, DESCRIPTIVE statistics

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer.

Authors: Christgen, Matthias, Gluz, Oleg, Harbeck, Nadia, Kates, Ronald E., Raap, Mieke, Christgen, Henriette, Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Krabisch, Petra, Just, Marianne, Augustin, Doris, Graeser, Monika, Baehner, Frederick, Wuerstlein, Rachel, Nitz, Ulrike

Source: Cancer (0008543X); Nov2020, Vol. 126 Issue 22, p4847-4858, 12p

Subject Terms: HORMONE receptor positive breast cancer, LOBULAR carcinoma, BREAST cancer, PROPORTIONAL hazards models, GENE expression profiling, TUMOR classification, PROGESTERONE receptors

Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial

Authors: Graeser, Monika Karla¹ (AUTHOR), Gluz, Oleg¹ (AUTHOR), Nitz, Ulrike¹ (AUTHOR), Biehl, Claudia² (AUTHOR), Berg, Angela¹ (AUTHOR), Christgen, Matthias³ (AUTHOR), Kuemmel, Sherko¹ (AUTHOR), Holtschmidt, Johannes⁴ (AUTHOR), Schumacher, Johannes⁵ (AUTHOR), Hartkopf, Andreas D.⁶ (AUTHOR), Potenberg, Jochem⁷ (AUTHOR), Luedtke-Heckenkamp, Kerstin⁸ (AUTHOR), Just, Marianne⁹ (AUTHOR), Schem, Christian¹⁰ (AUTHOR), zu Eulenburg, Christine¹ (AUTHOR), Schinkoethe, Timo¹¹ (AUTHOR), Wuerstlein, Rachel¹ (AUTHOR), Kates, Ronald E.¹ (AUTHOR), Kreipe, Hans Heinrich³ (AUTHOR), Harbeck, Nadia¹ (AUTHOR)

Source: Journal of Clinical Oncology. 2023 Supplement 16, Vol. 41, p519-519. 1p.